Repatha (Evolocumab) in Patients 65 and Older: Transition to Adult Care Guide

Why Age 65 Marks a Clinical Inflection Point for Evolocumab Therapy

Turning 65 changes three things simultaneously for patients on evolocumab: insurance status shifts toward Medicare, care coordination often transfers from a cardiologist or lipidologist to a primary care or geriatric medicine provider, and the physiological backdrop of aging introduces new variables that did not exist at the time of initial prescribing.

Cardiovascular disease remains the leading cause of death in adults 65 and older in the United States, accounting for approximately 24% of all deaths in that age group according to CDC data [1]. Given that LDL-C lowering is the cornerstone of atherosclerotic cardiovascular disease (ASCVD) risk reduction, continuing evolocumab therapy through and after this transition is medically justified for most patients who are tolerating it well.

The Biology of LDL-C in Older Adults

LDL-C metabolism does not improve with age. Hepatic LDL receptor expression tends to decline, and the contribution of dietary cholesterol to circulating LDL increases relative to younger adults [2]. PCSK9 inhibition by evolocumab restores LDL receptor cycling and lowers LDL-C by an average of 59% even against a background of maximally tolerated statin therapy, a benefit that is preserved in older subgroups [3].

What "Transition to Adult Care" Means in Practice

For most patients, this phrase describes the moment a specialist (interventional cardiologist, lipid clinic, endocrinologist) hands off long-term management to an outpatient primary care provider or geriatrician. The handoff is not merely administrative. The receiving clinician inherits responsibility for injection education, prior authorization renewals, adverse event monitoring, and integration of evolocumab into what may be a 10-to-15 drug regimen.

A structured care-transition checklist, including a reconciled medication list, documented injection-site technique assessment, and a 90-day follow-up lipid panel, reduces the likelihood of therapy discontinuation at handoff.

Evolocumab Dosing in Patients 65 and Older

No geriatric dose adjustment is required. The FDA prescribing label for evolocumab states explicitly that no clinically meaningful differences in pharmacokinetics or pharmacodynamics were observed in patients 65 years and older compared with younger adults [4].

Standard Regimens

Two regimens are available and interchangeable in terms of LDL-C lowering [4]:

| Regimen | Dose | Frequency | Device | |---|---|---|---| | Biweekly | 140 mg | Every 14 days | Single-use prefilled autoinjector or syringe | | Monthly | 420 mg | Once per month | Three consecutive 140 mg injections within 30 minutes, or single-use prefilled cartridge with the SureClick autoinjector |

For patients with dexterity limitations, arthritis, or visual impairment, the monthly 420 mg option with the on-body device or the biweekly autoinjector may be easier to use than the three-injection monthly protocol. An occupational therapy consultation is appropriate when self-injection ability is uncertain.

Pharmacokinetics in Aging Physiology

Evolocumab is a fully human monoclonal IgG2 antibody. Its clearance is primarily proteolytic rather than hepatic or renal, so age-related declines in creatinine clearance do not require dose modification [4]. Body weight does influence exposure: patients with body weight below 60 kg show slightly higher area under the curve, but no toxicity threshold has been identified that changes clinical practice in this population.

Evidence Base: What FOURIER and Other Trials Show in Older Patients

The FOURIER trial (N=27,564) randomly assigned patients with established ASCVD and LDL-C 70 mg/dL or above on optimized statin therapy to evolocumab or placebo. The primary composite endpoint of CV death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization was reduced by 15% with evolocumab (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [3].

Geriatric Subgroup Performance

A pre-specified subgroup analysis within FOURIER demonstrated that patients 65 and older experienced consistent benefit with no significant interaction by age subgroup [3]. The absolute risk reduction was numerically larger in older patients because their baseline event rate was higher, a pattern consistent with the principle that higher-risk patients gain more from the same relative risk reduction.

The GLAGOV trial (N=968), which measured coronary atheroma volume by intravascular ultrasound, found that evolocumab produced significant regression of atherosclerotic plaque at 78 weeks in patients across a broad age range [5]. Plaque regression occurred at a mean achieved LDL-C of 36.6 mg/dL.

Statin-Intolerant Patients: A Particularly Important Older Subgroup

Statin intolerance prevalence increases with age due to the higher rate of muscle-related comorbidities, polypharmacy with CYP3A4-metabolized drugs, and age-related decline in skeletal muscle mass. The GAUSS-3 trial (N=511) showed that evolocumab reduced LDL-C by 52.8% in patients who had failed two or more statins due to muscle symptoms, compared with a 1.8% reduction with ezetimibe (P<0.001) [6]. This makes evolocumab a primary option, not a fallback, for older patients with confirmed statin intolerance.

Safety Profile Relevant to Geriatric Patients

The safety profile of evolocumab in older adults is well-characterized across the FOURIER and OSLER trials. Rates of serious adverse events were comparable between evolocumab and placebo in the geriatric subgroup [3].

Musculoskeletal and Neurocognitive Concerns

Early observational concerns about PCSK9 inhibitors causing cognitive decline were not confirmed in controlled trial data. The EBBINGHAUS trial, a prospective cognitive substudy of FOURIER (N=1,974), found no statistically significant difference between evolocumab and placebo on the primary cognitive endpoint (spatial working memory strategy index) after a median follow-up of 19 months [7]. This is particularly relevant to older patients and families who ask about memory side effects.

Myalgia occurs in roughly 5% of patients on evolocumab versus 4.8% on placebo in clinical trials, a difference that is not statistically significant. This should be reassuring when a geriatric patient reports new muscle aches, since evolocumab is unlikely to be the cause.

Injection-Site Reactions

Injection-site reactions occur in approximately 3.1% of evolocumab-treated patients versus 2.5% of placebo patients [4]. For older patients with thinned subcutaneous tissue, rotating injection sites (abdomen, upper thigh, upper arm) and allowing the device to reach room temperature before use reduces local discomfort.

Renal and Hepatic Considerations

Mild to moderate chronic kidney disease (CKD stages 1 to 3, GFR 30 to 89 mL/min/1.73m²) does not require dose modification. Data in severe CKD (GFR <15) or dialysis-dependent patients remain limited, and clinical judgment governs use in that setting [4]. No hepatic dose adjustment is required for mild or moderate hepatic impairment; evolocumab has not been studied in severe hepatic impairment (Child-Pugh C).

LDL-C Targets in Patients 65 and Older

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states that for patients with clinical ASCVD at very high risk, an LDL-C goal of less than 70 mg/dL is recommended, with an optional target of less than 55 mg/dL for those with multiple high-risk features [8]. The American Association of Clinical Endocrinology (AACE) 2022 Dyslipidemia Guidelines set an LDL-C target of less than 55 mg/dL for patients in the "extreme risk" category, which includes most geriatric patients with established coronary disease [9].

Applying Targets at the Transition Visit

At the transition appointment, the receiving provider should:

1. Pull a fasting lipid panel if one has not been obtained within the past 3 months.
2. Confirm whether the patient is at LDL-C goal per the applicable guideline.
3. If LDL-C is above goal, assess adherence before attributing failure to the drug.
4. If LDL-C is well below 40 mg/dL consistently, discuss with the patient whether the current regimen intensity matches goals of care, particularly in frailty or limited life expectancy.

The ACC/AHA guideline notes: "In patients 75 years of age or older, it is reasonable to continue statin therapy [and adjunctive LDL-lowering therapy] in those who are tolerating it and have an established ASCVD" [8].

Very Low LDL-C: Is There a Floor?

FOURIER achieved a median on-treatment LDL-C of 30 mg/dL in the evolocumab arm with no significant increase in adverse events, including hemorrhagic stroke, adrenal insufficiency, or cognitive impairment [3]. There is no identified harmful LDL-C floor in controlled trial data to date.

Medicare Coverage and Prior Authorization for Evolocumab

Medicare Part D covers evolocumab, but it is subject to prior authorization at virtually every plan because of its list price of approximately $5,850 per year after recent manufacturer rebates. The actual cost to the patient depends heavily on the specific Part D plan formulary tier.

Prior Authorization Criteria Commonly Required

Most Medicare Part D plans require documentation of:

• Diagnosis of clinical ASCVD or familial hypercholesterolemia (FH)
• Current maximally tolerated statin therapy (or documented statin intolerance)
• LDL-C above threshold (typically 70 mg/dL or 100 mg/dL depending on plan)
• One failed trial of ezetimibe (some plans require this; others do not)

The transition visit is the right time to verify that the prior authorization is active, identify the renewal date, and confirm that the receiving provider is prepared to complete renewals on behalf of the patient.

Amgen Patient Assistance

For patients who fall into the Medicare Part D coverage gap or face high out-of-pocket costs, Amgen's Repatha SupportPlus program offers copay assistance and free-drug programs for eligible patients. Patients can be directed to amgen.com or 1-844-REPATHA for enrollment assistance. This is not a substitute for provider-level prior authorization management.

Polypharmacy Assessment at the Transition Visit

Geriatric patients taking evolocumab frequently take 8 to 12 other medications. Evolocumab has no known pharmacokinetic drug-drug interactions because it does not use cytochrome P450 pathways [4]. This is a practical advantage over statins, many of which interact with CYP3A4 or CYP2C9 substrates common in older patients (amlodipine, warfarin, amiodarone, clarithromycin).

The absence of drug interactions does not eliminate the need for polypharmacy review. The transition visit should flag drugs that increase bleeding risk (if the patient has had a hemorrhagic event) and reconcile any cardiovascular medications added since the last specialist visit that could overlap in mechanism or adverse effect profile.

Frailty and Goals of Care

Frailty assessment (using the Clinical Frailty Scale or FRAIL questionnaire) is appropriate for patients 75 and older at the transition visit. For patients with a Clinical Frailty Scale score of 7 or above (severely frail), the risk-benefit calculation for aggressive LDL-C lowering shifts. The 2022 ACC Expert Consensus Decision Pathway for Geriatric Cardiology acknowledges that treatment intensity should be individualized based on functional status, life expectancy, and patient preferences [10].

Evolocumab therapy need not be stopped in frail patients automatically. Discussing goals of care explicitly and documenting that conversation is the appropriate standard.

Injection Education and Device Selection at Transition

Self-injection competency should be re-evaluated at the transition visit, not assumed. Studies of older adults managing injectable biologics show that technique errors (insufficient skin pinch, incomplete needle insertion, not holding the device for the full count) are common and increase with time since initial training [11].

Device Options for Older Adults

Amgen currently markets evolocumab in two injection systems:

• SureClick autoinjector (140 mg/mL in 1 mL): A push-and-click device suitable for most patients. Requires audible click confirmation.
• Pushtronex system (420 mg/3.5 mL): A wearable on-body infusor worn on the abdomen for approximately 9 minutes once monthly. This device eliminates the need for multiple injections and may suit patients with significant hand tremor or reduced grip strength.

The receiving provider or a trained nurse should observe at least one injection during the transition visit and document competency. If the patient cannot self-inject reliably, options include a home health aide, visiting nurse, or caregiver training.

Monitoring Schedule After Transition

The ACC/AHA recommends a fasting lipid panel 4 to 12 weeks after initiation or dose change of any LDL-lowering therapy, then every 3 to 12 months thereafter to confirm adherence and goal attainment [8]. For a stable patient transitioning care, the following schedule is reasonable:

| Timepoint | Assessment | |---|---| | Transition visit | Lipid panel, CMP, medication reconciliation, injection technique review, PA renewal confirmation | | 6 weeks post-transition | Fasting lipid panel if recent change in statin co-therapy | | 3 months | Adherence check, any new musculoskeletal symptoms, injection-site assessment | | 12 months | Annual lipid panel, frailty reassessment in patients 75 and older, PA renewal |

Liver function testing is not required at routine intervals for evolocumab; the drug does not cause hepatotoxicity and the FDA prescribing label includes no routine LFT monitoring requirement [4].